Mogamulizumab, referred to as KW-0761 and bearing the chemical identifier 1159266-37-1, represents a novel approach to managing cutaneous T-cell lymphoma (CTCL). This engineered monoclonal protein selectively targets https://www.targetmol.com/compound/mogamulizumab